Hormone research in paediatrics
Audio Summaries

PREDICTORS OF RESPONSE TO GROWTH HORMONE TREATMENT AND FINAL HEIGHT IN MEDULLOBLASTOMA SURVIVORS

Jun 11, 2026

The authors investigate the growth characteristics and response to growth hormone treatment (GHT) in survivors of childhood medulloblastoma, aiming to identify factors influencing final height (FH) outcomes. Their findings indicate that a significant majority of patients experience growth retardation and GH deficiency, with early height-SDS at the start of treatment being the key predictor of FH success. The study emphasizes the importance of timely GH deficiency diagnosis and treatment while highlighting concerns regarding the long-term safety of GHT.

The Use Of EQ5D For Assessment Of Health Related Quality Of Life And Its Determinants In Children With Complex Endocrine Conditions

Jun 10, 2026

The authors aim to evaluate the utility of the EQ5D tool for assessing health-related quality of life (QoL) in children with complex endocrine conditions. Their study, involving 216 patients, reveals that the EQ5D scores correlate with the complexity of medical care, indicating that a higher number of specialties involved is associated with worse QoL outcomes. The findings suggest that EQ5D is a valuable instrument for routine QoL assessment in pediatric endocrinology.

Impact of Early Initiation of Automated Insulin Delivery on Glycemia Two Years from Type 1 Diabetes Diagnosis

Jun 3, 2026

The authors aimed to determine whether the high time in range (TIR) achieved through automated insulin delivery (AID) in youth with type 1 diabetes (T1D) shortly after diagnosis would persist over a two-year period. Their analysis found that while the TIR remained stable in the control group, it declined significantly in the AID group from 79% to 67% over the second year, with no significant differences in overall glycemic control between the two groups at 104 weeks. This suggests that the benefits of early AID initiation may diminish over time.